Biotechnology - Anti-virals, Vaccines

Filter

Current filters:

Anti-viralsVaccines

Popular Filters

Dynavax withdraws European MAA for Heplisav

18-02-2014

US biotech firm Dynavax Technologies says it has withdrawn the European Marketing Authorization Application…

Anti-viralsBiotechnologyDynavax TechnologiesEuropeHeplisavRegulationVaccines

Creation of ABIVAX - a leader in therapeutic vaccines - in a Cuban collaboration

12-02-2014

French venture capital firm Truffle Capital has announced the creation of Paris-based ABIVAX in collaboration…

ABIVAXAnti-viralsBiotechnologyResearchVaccines

Vivaldi Biosciences acquires clinical stage influenza vaccine assets

13-10-2013

Privately-held US biotech firm Vivaldi Biosciences has acquired from Baxter Healthcare R&D assets, including…

Anti-viralsBaxter HealthcareBaxter InternationalBiotechnologyMergers & AcquisitionsVaccinesVivaldi Biosciences

Valneva licenses EB66 to IAVI for preventive HIV vaccine

02-10-2013

Biotech firm Valneva says that it has licensed the use of its EB66 cell line to the International AIDS…

Anti-viralsBiotechnologyLicensingVaccinesValneva

Immune Design and Medicago link up to develop flu vaccines

01-07-2013

Privately-held US biotech firm Immune Design and Medicago (TSX: MDG), a Canadian biopharmaceutical company…

Anti-viralsBiotechnologyImmune DesignLicensingMedicagoVaccines

Negative FDA news for AVEO's tivozanib and Dynavax' hep B vaccine

11-06-2013

US biotech firm AVEO Oncology (Nasdaq: AVEO) says that it has received a complete response letter from…

Anti-viralsAstellas PharmaAVEO OncologyBiotechnologyDynavax TechnologiesHeplisavNorth AmericaOncologyPharmaceuticalRegulationtivozanibVaccines

HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst

20-05-2013

While the risks involved in HIV vaccine development have turned Big Pharma away from pursuing a preventative…

Anti-viralsBiotechnologyFinancialHVTN 505PharmaceuticalResearchVaccines

FDA delays approval of Dynavax' Heplisav, issuing CRL

26-02-2013

Dynavax Technologies ( Nasdaq: DVAX) saw its shares plunge as much as 38% to $1.84 in pre-market trading…

Anti-viralsBiotechnologyDynavax TechnologiesHeplisavNorth AmericaRegulationVaccines

Generex highlights pipeline potential of Antigen Express subsidiary

10-02-2013

Canada-based Generex Biotechnology (OTC Bulletin Board: GNBT) last week provided an overview of the current…

AE37Anti-viralsAntigen ExpressBiotechnologyGenerex BiotechnologyOncologyPharmaceuticalResearchVaccines

FDA approves Protein Sciences egg-free flu vaccine Flublok; and Octapharma's Octaplas

18-01-2013

The US Food and Drug Administration revealed it has approved privately-held US biotech firm Protein Sciences…

Anti-viralsBiotechnologyFlublokMergers & AcquisitionsNorth AmericaOctapharmaOctaplasPanblokPharmaceuticalProtein Sciences CorpRegulationVaccines

EMA accepts Dynavax' filing for hep B drug Heplisav

23-08-2012

US biotech firm Dynavax Technologies (Nasdaq: DVAX) revealed yesterday that the European Medicines Agency…

Anti-viralsBiotechnologyDynavax TechnologiesEuropeHeplisavRegulationVaccines

Crucell and Scripps Research discover broad-spectrum antibodies against influenza B

12-08-2012

In what is described as a landmark discovery, researchers from Crucell Holland, which became wholly-owned…

Anti-viralsBiotechnologyCrucellJohnson & JohnsonPharmaceuticalResearchVaccines

Silencing investor concerns? Alnylam achieves RNAi milestone

02-08-2012

US RNAi therapeutics specialties Alnylam Pharmaceuticals (Nasdaq: ALNY) has received a $3.2 million milestone…

Alnylam PharmaceuticalsAnti-viralsBiotechnologyFinancialGlaxoSmithKlineLicensingProductionVaccines

RusNano to start production of vaccines and organogels

09-01-2012

Russia’s RusNano (Russian Corporation of Nanotechnologies) has signed an agreement with Russian…

Anti-viralsBiotechnologyCardio-vascularEpidbiomedEuropeFinancialMarkets & MarketingMergers & AcquisitionsNanolekOncologyRusNanoVaccines

Gilead collaborates with GlobeImmune to develop vaccine for chronic hepatitis B infection

25-10-2011

Gilead Sciences (Nasdaq: GILD) has entered into an exclusive worldwide license and collaboration agreement…

Anti-viralsBiotechnologyGilead SciencesGlobeImmuneLicensingResearchVaccines

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top